Brief: Novocure Announces Portfolio Prioritization And Strategic Restructuring Plan

NovoCure

28/11/2023 15:22

Nov 28 (Reuters) - Novocure Ltd  NVCR.O :
    * NOVOCURE ANNOUNCES PORTFOLIO PRIORITIZATION AND STRATEGIC
RESTRUCTURING PLAN FOCUSED ON NEAR-TERM GROWTH DRIVERS AND AN
ACCELERATED PATH TO PROFITABILITY
    * NOVOCURE ANNOUNCES PORTFOLIO PRIORITIZATION AND STRATEGIC
RESTRUCTURING PLAN FOCUSED ON NEAR-TERM GROWTH DRIVERS AND AN
ACCELERATED PATH TO PROFITABILITY
    * NOVOCURE LTD - EXPECTED REDUCTION IN RESIDUAL OPERATING
EXPENSES
OF APPROXIMATELY $60 MILLION
    * NOVOCURE LTD - EXPECTED REDUCTION IN RESIDUAL OPERATING
EXPENSES
OF APPROXIMATELY $60 MILLION
    * NOVOCURE LTD - REDUCTION IN HEADCOUNT OF APPROXIMATELY 200
COLLEAGUES, 13% OF TOTAL WORKFORCE
    * NOVOCURE LTD - EXPECTED REDUCTION IN RESIDUAL OPERATING
EXPENSES
OF APPROXIMATELY $60 MILLION, INCLUDING A REDUCTION IN HEADCOUNT
OF APPROXIMATELY 200 COLLEAGUES
    * NOVOCURE LTD: REDUCTION IN HEADCOUNT OF APPROXIMATELY 200
COLLEAGUES, 13% OF TOTAL WORKFORCE
    * NOVOCURE LTD - PRIORITIZED DEVELOPMENT INVESTMENTS ON A
SHARPLY
FOCUSED LIST OF RANDOMIZED CLINICAL TRIALS - TRIDENT, KEYNOTE
D58 AND LUNAR-2
    * NOVOCURE LTD - NOVOCURE EXPECTS TO INCUR ONE-TIME COSTS
RELATED
TO WORKFORCE REDUCTION OF APPROXIMATELY $7 MILLION IN Q4 OF
2023.
    * NOVOCURE LTD - EXPECTS TO INCUR ONE-TIME COSTS RELATED TO
WORKFORCE REDUCTION OF APPROXIMATELY $7 MILLION IN Q4 OF 2023
    * NOVOCURE LTD - FIELD-BASED COMMERCIAL AND FIELD-BASED
MEDICAL
EMPLOYEES ARE MINIMALLY AFFECTED PLANNED BY REDUCTION IN
HEADCOUNT

Source text for Eikon:  ID:nBwbjsh8Wa 
Further company coverage:  NVCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))